4月1日，诺禾致源今日收盘15.41元，上涨2.60%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到32.98倍，总市值64.14亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均52.86倍，行业中值49.90倍，诺禾致源排 名第22位。 截至2024年三季报，共有132家机构持仓诺禾致源，其中基金132家，合计持股数3579.96万股，持股市 值4.47亿元。 北京诺禾致源科技股份有限公司主营业务是生命科学基础研究、医学及临床应用研究提供多层次的科研 技术服务及解决方案，同时自主开发创新的基因检测医疗器械。主要产品有生命科学基础科研服务、医 学研究与技术服务、建库测序平台服务。公司积极开拓基因技术在临床应用的发展。公司第三类医疗器 械"人EGFR、KRAS、BRAF、PIK3CA、ALK、ROS1基因突变检测试剂盒（半导体测序法）"于2018年 8月通过NMPA创新医疗器械特别审评通道审批上市，成为我国首批获准上市的基于高通量测序的肿瘤 基因检测试剂盒之一，是国内唯一的配套分析软件亦取得第三类医疗器械注册证的肿瘤分子检测产品， 也是国内临床试验样本量最大的基因检测获批产品。 最 ...

中信证券股份有限公司 关于北京诺禾致源科技股份有限公司 部分募投项目延期的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为北京诺禾致 源科技股份有限公司（以下简称"诺禾致源"或"公司"）2022 年向特定对象发行股 票的持续督导保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交 易所科创板股票上市规则》《上市公司监管指引第 2 号——上市公司募集资金管 理和使用的监管要求》以及《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对诺禾致源部分募投项目延期的事项进行了审慎 核查，核查情况如下： 一、募集资金基本情况 2022 年 11 月 10 日，中国证监会出具了《关于同意北京诺禾致源科技股份 有限公司向特定对象发行股票注册的批复》（证监许可﹝2022﹞2813 号），同意 公司 2022 年度向特定对象发行 A 股股票注册申请。公司本次向特定对象发行 16,000,000 股 A 股股票，发行价格为每股 20.76 元，募集资金总额为人民币 332,160,000.00 元，扣除不含增值税的发行费用人民币 4,551,356.60 元后，实际 募集资金 ...

证券代码：688315 证券简称：诺禾致源 公告编号：2025-007 北京诺禾致源科技股份有限公司 关于部分募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京诺禾致源科技股份有限公司（以下简称"公司"）于 2025 年 3 月 21 日 召开了第三届董事会第二十次会议和第三届监事会第十八次会议，审议通过了 《关于部分募投项目延期的议案》，同意公司将 2022 年度向特定对象发行 A 股 股票募集资金投资项目"实验室新建及扩建项目——基因测序服务中心建设项目 （天津武清）"、"实验室新建及扩建项目——美国实验室新建项目"达到预定 可使用状态的日期进行延期。公司保荐人中信证券股份有限公司对该事项出具了 明确无异议的核查意见，该事项无需提交公司股东大会审议。现将相关情况公告 如下： 一、募集资金基本情况 2022 年 11 月 10 日，中国证监会出具了《关于同意北京诺禾致源科技股份 有限公司向特定对象发行股票注册的批复》（证监许可﹝2022﹞2813 号），同意 公司 2022 年度向特定对象发行 A ...

证券代码：688315 证券简称：诺禾致源 公告编号：2025-008 北京诺禾致源科技股份有限公司 第三届监事会第十八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京诺禾致源科技股份有限公司（以下简称"公司"）第三届监事会第十八 次会议（以下简称"本次会议"）于 2025 年 3 月 21 日召开，公司已于 2025 年 3 月 16 日以邮件、电话等方式向公司全体监事发出了会议通知。本次会议由监事 会主席李兴园女士召集并主持，应参加本次监事会会议的监事 3 人，实际参加本 次监事会会议的监事 3 人。会议符合《中华人民共和国公司法》和《北京诺禾致 源科技股份有限公司章程》（以下简称"《公司章程》"）及有关法律法规要求。 会议审议并通过了如下议案： 北京诺禾致源科技股份有限公司监事会 2025 年 3 月 22 日 1 公司监事会认为：公司本次对部分募投项目延期，不存在改变或变相改变 募集资金投向，不存在损害公司和全体股东尤其是中小股东利益的情形，符合中 国证监会、上海证券交易所关于上市公司募集资金管 ...

证券代码：688315 证券简称：诺禾致源 公告编号：2025-006 北京诺禾致源科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 截至本公告披露日，北京诺禾致源科技股份有限公司（以下简称"公司"或 "诺禾致源"）股东北京致源禾谷投资管理中心(有限合伙)（以下简称"致源禾 谷"）持有公司 47,106,622 股股份，占公司总股份的 11.32%；北京诺禾禾谷投 资管理中心（有限合伙）（以下简称"诺禾禾谷"）持有公司 12,564,672 股股份， 占公司总股份的 3.02%。上述股份为致源禾谷和诺禾禾谷于公司首次公开发行并 上市前取得的股份，且于 2024 年 4 月 15 日起上市流通。 减持计划的主要内容 公司于近日收到致源禾谷和诺禾禾谷出具的《关于股份减持计划的告知函》， 因自身资金安排，致源禾谷和诺禾禾谷计划根据市场情况通过集中竞价、大宗交 易进行减持： 致源禾谷和诺禾禾谷计划通过集中竞价、大宗交易方式减持诺禾致源股份合 计 ...

致源禾谷和诺禾禾谷的普通合伙人、执行事务合伙人均为公司控股股东、实控人李瑞强。 人民财讯3月19日电，诺禾致源(688315)3月19日晚间公告，公司股东致源禾谷、诺禾禾谷合计持有公司 14.34%股份，计划通过集中竞价、大宗交易方式减持公司股份合计不超1248.6万股，占公司总股份的 3%。 ...

Investment Rating - The industry investment rating is "Recommended" [1] Core Viewpoints - The report highlights a revolution in sequencing technology empowered by AI, with domestic companies accelerating their AI business layout [5][6] - The domestic sequencing market is rapidly growing, with China becoming the second-largest gene testing market globally, surpassing 33.5 billion RMB in 2024 [31] - AI technology is significantly reducing costs and enhancing the efficiency and accuracy of sequencing processes, leading to advancements in personalized treatment and drug development [32] Summary by Sections Industry Overview - The pharmaceutical and biotechnology industry includes 645 listed companies with a total share capital of 5,825.23 million shares and sales revenue of 37,462.19 billion RMB [1] - The total profit for the industry is 3,382.22 billion RMB, with an average PE ratio of 42.37 [1] Market Performance - The pharmaceutical index increased by 1.06% during the week of March 3-7, 2025, underperforming the CSI 300 index, which rose by 1.39% [7][9] - The pharmaceutical industry index PE (TTM, excluding negative values) is 26.65 times, with a valuation premium of 121.81% compared to the CSI 300 index, indicating a historical low [9] AI Empowerment in Sequencing Technology - AI is optimizing sequencing processes and data analysis algorithms, enhancing speed and accuracy [31] - Domestic companies like BGI and Tempus are leveraging AI to create closed-loop ecosystems for data analysis and clinical applications [20][21] - The report emphasizes the importance of AI in reducing detection costs and improving personalized treatment options [32] Key Companies and Developments - Tempus AI focuses on integrating AI with clinical diagnostics, utilizing a vast database for drug development and clinical trial optimization [20][21] - BGI is enhancing sequencing efficiency through AI tools and has established a significant presence in over 100 countries [32] - Other notable companies include Shengxiang Biology, Novogene, and Berry Genomics, all of which are advancing their AI capabilities in sequencing and diagnostics [34][35]

Investment Rating - The report assigns an investment rating of "Recommended" for the pharmaceutical and biotechnology industry [3][33]. Core Insights - The "AI + Healthcare/Pharmaceutical" theme continues to gain traction, with short-term momentum expected to persist. The report highlights significant stock performance in the sector, with the pharmaceutical and biotechnology sector (SW) rising by 2.71%, outperforming the CSI 300 index, and all sub-sectors showing positive growth, particularly in medical services [3][4]. - In the U.S., Tempus AI, a representative company in medical AI, saw a weekly increase of approximately 30% and over 160% year-to-date, driving the momentum of the medical AI concept. In China, companies like KingMed Diagnostics and Dian Diagnostics announced collaborations with DeepSeek, indicating a shift towards the commercialization of AI applications in healthcare [4][3]. - The report emphasizes investment opportunities in sub-sectors such as "AI + Medical Imaging," "AI + Diagnostic Services," and "AI + Drug Development," recommending key companies including United Imaging, Mindray, BGI Genomics, and WuXi AppTec [3][4]. Industry Performance Tracking - The pharmaceutical and biotechnology sector (SW) rose by 2.71% in the week of February 10-14, ranking 5th among 31 Shenwan primary industries. The CSI 300 index increased by 1.19% during the same period [5][6]. - All sub-sectors experienced growth, with medical services leading at +6.51%, followed by medical devices at +4.81%, and pharmaceutical commerce at +4.18% [5][6]. - Notable individual stock performances included Dian Diagnostics (+46.29%), Mian Health (+31.58%), and United Imaging (+27.33%) [6]. Industry Dynamics and Key Company Tracking - The National Healthcare Security Administration released a list of key tasks for 2025, focusing on efficient medical insurance processes and direct settlements for collected drugs and consumables [7]. - The retail terminal drug sales scale in China is projected to reach 574 billion yuan in 2024, with a growth rate of 3.7%, indicating a slowdown in growth due to demographic and economic factors [8]. - The report also notes significant collaborations, such as Baiyang Pharmaceutical's agreement with Roche for the exclusive marketing rights of a targeted cancer drug in mainland China [9][11]. Industry Data Tracking - The report tracks various industry metrics, including the basic medical insurance fund income, which reached 28,507.29 billion yuan in 2024, showing a year-on-year growth of 5% [15][16]. - The domestic pharmaceutical manufacturing industry achieved a total revenue of 25,298.50 billion yuan in 2024, with profit totals declining by 1.1% year-on-year [17].

Investment Rating - The report assigns an investment rating of "Recommended" for the pharmaceutical and biotechnology industry [3][33]. Core Insights - The "AI + Healthcare/Pharmaceutical" theme continues to gain traction, with short-term momentum expected to persist. The domestic and international markets are witnessing significant developments in AI applications within healthcare, particularly with companies like Tempus AI showing substantial stock price increases [3][4]. - The report highlights investment opportunities in specific segments such as "AI + Medical Imaging," "AI + Diagnostic Services," and "AI + Drug Development," recommending key companies including United Imaging, Mindray, BGI, and WuXi AppTec [3][4]. Industry Performance Tracking - The pharmaceutical and biotechnology sector (SW) rose by 2.71% last week, outperforming the CSI 300 index, which increased by 1.19%. All sub-sectors within the industry experienced growth, with medical services leading at +6.51% [5][6]. - Notable individual stock performances included Dean Diagnostics (+46.29%) and Meinian Health (+31.58%), while stocks like Betta Pharmaceuticals saw declines of -11.36% [6]. Industry Dynamics and Key Company Tracking - The National Healthcare Security Administration released a list of key tasks for 2025, focusing on efficient medical insurance processes and direct settlements for collected drugs and consumables [7]. - Recent collaborations include Baiyang Pharmaceutical signing a commercialization agreement with Roche for the drug Rituximab, and Sanofi Biologics partnering with Baili Tianheng to explore new treatment potentials in oncology [11][12]. Industry Data Tracking - The retail terminal drug sales in China are projected to reach CNY 574 billion in 2024, with a growth rate of 3.7%, indicating a slowdown compared to previous years [8]. - The medical insurance fund's income for 2024 is reported at CNY 28,507.29 billion, reflecting a year-on-year growth of 5.00% [15][16]. - The domestic pharmaceutical manufacturing industry achieved a total revenue of CNY 25,298.50 billion in 2024, remaining stable compared to the previous year [17].

Financial Performance - Total operating revenue for 2024 reached RMB 2,111.32 million, a year-on-year increase of 5.45%[3] - Net profit attributable to shareholders of the parent company was RMB 1,944.48 million, reflecting a growth of 9.20% compared to the previous year[3] - Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was RMB 1,672.88 million, up 19.50% year-on-year[3] - Basic earnings per share rose to RMB 0.48, a 9.09% increase from the previous year[3] - The weighted average return on net assets decreased to 7.93%, down 0.55 percentage points from the previous year[3] Assets and Equity - Total assets at the end of the reporting period amounted to RMB 36,366.04 million, an increase of 1.17% from the end of 2023[6] - Shareholders' equity attributable to the parent company was RMB 24,889.76 million, growing by 1.28% compared to the end of 2023[6] Strategic Initiatives - The company emphasized a strategy of total cost leadership and expanded overseas market presence to boost revenue[6] - Increased investment in new product and technology development to enhance innovation capabilities[6] Profitability Metrics - The company reported improvements in gross margin and profit margin, indicating enhanced profitability metrics[6]